---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-26-000055"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2026-08-13T20:59:21+00:00"
generated_at: "2026-08-13T21:00:07.753216+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Instil Bio Q2 2026 net loss $0.63/share; cash $69.9M funds beyond 2027

## Summary
- Cash, equivalents, restricted cash and marketable securities $69.9M at June 30, 2026, down from $76.3M at Dec 31, 2025.
- Q2 2026 net loss per share $0.63 (basic/diluted) vs $3.24 in Q2 2025; non-GAAP $0.45 vs $2.88.
- R&D expenses $0.3M in Q2 2026 vs $6.7M in Q2 2025; G&A $5.1M vs $6.2M.
- In-process R&D expenses nil vs $10.0M in Q2 2025; restructuring charges $0.2M vs $0.5M.
- Company evaluating potential acquisitions, in-licensing opportunities for novel therapeutic candidates.

## SEC filing metadata
- accession: 0001789769-26-000055
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2026-08-13T20:59:21+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976926000055/0001789769-26-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976926000055/til-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-26-000055
- JSON: https://secwatch.observer/filing/0001789769-26-000055.json
- Plain text: https://secwatch.observer/filing/0001789769-26-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.